{'fraction_non_alphanumeric': 0.019101123595505618, 'fraction_numerical': 0.011235955056179775, 'mean_word_length': 5.6, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Synthetic Lethal Approaches to Metastatic Breast Cancer Therapy

Breast cancer is the most commonly diagnosed cancer in women and each year approximately 1.7 million new cases are detected globally. Metastatic breast cancers are the most aggressive form of this disease, with an average survival rate of less than 2 years. We recently discovered a metastasis suppressor, CREB3L1 (cAMP responsive element binding protein 3‐like protein), which is frequently missing from metastatic breast cancer cells. CREB3L1 is expressed ubiquitously in non‐cancerous human breast cells and restricts expression of genes that promote cell growth, angiogenesis, and migration. Loss of CREB3L1 expression can result in enhanced metastatic properties and our analysis indicates that it is a frequent event in high‐grade metastatic human breast tumors, thus highlighting a potential target for cancer therapy.